[go: up one dir, main page]

UY30045A1 - Derivados de pirimidina - Google Patents

Derivados de pirimidina

Info

Publication number
UY30045A1
UY30045A1 UY30045A UY30045A UY30045A1 UY 30045 A1 UY30045 A1 UY 30045A1 UY 30045 A UY30045 A UY 30045A UY 30045 A UY30045 A UY 30045A UY 30045 A1 UY30045 A1 UY 30045A1
Authority
UY
Uruguay
Prior art keywords
pirimidine derivatives
pirimidine
derivatives
mime
pharmaceutically
Prior art date
Application number
UY30045A
Other languages
English (en)
Inventor
David Howard Williams
Nigel Alan Swain
Matthew Duncan Selby
Charles Eric Mowbray
Andrew Simon Bell
Charlotte Alice Louise Lane
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of UY30045A1 publication Critical patent/UY30045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de Fórmula (1): o un derivado farmacéutica y/o veterinariamente aceptable del mimo, en el que R1, R2, R3, R4, R5, y R8 son como se han definido anteriormente.
UY30045A 2005-12-20 2006-12-20 Derivados de pirimidina UY30045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75261205P 2005-12-20 2005-12-20

Publications (1)

Publication Number Publication Date
UY30045A1 true UY30045A1 (es) 2007-07-31

Family

ID=38124887

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30045A UY30045A1 (es) 2005-12-20 2006-12-20 Derivados de pirimidina

Country Status (36)

Country Link
US (1) US7943628B2 (es)
EP (1) EP1966162B1 (es)
JP (1) JP5166280B2 (es)
KR (2) KR20120025010A (es)
CN (1) CN101341134B (es)
AP (1) AP2008004486A0 (es)
AR (1) AR058557A1 (es)
AU (1) AU2006327876B2 (es)
BR (1) BRPI0620201A2 (es)
CA (1) CA2634018C (es)
CR (1) CR10061A (es)
CY (1) CY1118987T1 (es)
DK (1) DK1966162T3 (es)
DO (1) DOP2006000288A (es)
EA (1) EA200801381A1 (es)
EC (1) ECSP088559A (es)
ES (1) ES2628482T3 (es)
GT (1) GT200600518A (es)
HR (1) HRP20170896T1 (es)
HU (1) HUE034650T2 (es)
IL (1) IL191432A (es)
LT (1) LT1966162T (es)
MA (1) MA30082B1 (es)
ME (1) ME00004B (es)
NL (1) NL2000323C2 (es)
NO (1) NO341075B1 (es)
PE (1) PE20070848A1 (es)
PL (1) PL1966162T3 (es)
PT (1) PT1966162T (es)
RS (2) RS56102B1 (es)
SI (1) SI1966162T1 (es)
TN (1) TNSN08269A1 (es)
TW (1) TW200732306A (es)
UY (1) UY30045A1 (es)
WO (1) WO2007072163A2 (es)
ZA (1) ZA200805294B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290715A1 (en) * 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
US20080217501A1 (en) * 2007-02-14 2008-09-11 Chad Jensen Power a-frame
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2692720A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
PE20091035A1 (es) * 2007-11-30 2009-07-16 Palau Pharma Sa Derivados de 2-aminopirimidina
WO2009077608A1 (en) * 2007-12-19 2009-06-25 Palau Pharma, S. A. 2 -aminopyrimidine derivatives as histamine h4 antagonists
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN102118969B (zh) 2008-06-12 2017-03-08 詹森药业有限公司 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
WO2010075270A1 (en) * 2008-12-22 2010-07-01 Incyte Corporation 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
WO2010108059A1 (en) 2009-03-20 2010-09-23 Incyte Corporation Substituted pyrimidine derivatives as antagonists of the histamine h4 receptor
FR2945533B1 (fr) * 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
AU2010311378B2 (en) 2009-10-29 2014-04-24 Vectura Limited N-containing heteroaryl derivatives as JAK3 kinase inhibitors
PE20121505A1 (es) 2009-12-23 2012-11-05 Medicis Pharmaceutical Corp Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
JP6039683B2 (ja) 2011-11-23 2016-12-07 ポートラ ファーマシューティカルズ， インコーポレイテッド ピラジンキナーゼ阻害剤
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
AU2013263420A1 (en) * 2012-05-15 2015-01-22 Calasia Pharmaceuticals, Inc. Pyrimidine diamine derivatives as inhibitors of cytosolic Hsp90
FR2990859B1 (fr) * 2012-05-24 2014-05-23 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
US9688989B2 (en) 2012-06-08 2017-06-27 Sensorion H4 receptor inhibitors for treating tinnitus
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
EP3053926B1 (en) 2013-09-30 2018-08-08 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
US10125144B2 (en) 2013-10-07 2018-11-13 Kadmon Corporation, Llc Rho kinase inhibitors
JP6139789B2 (ja) 2013-10-16 2017-05-31 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合複素環化合物、その調製方法、医薬組成物及びその使用
EP3085700B1 (en) * 2013-12-20 2018-10-31 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Novel piperidine carboxamide compound, preparation method, and usage thereof
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
NO2721710T3 (es) * 2014-08-21 2018-03-31
AU2016218569A1 (en) * 2015-02-13 2017-09-28 Merck Patent Gmbh Pyrimidine derivatives for use in the treatment of cancer
TW201729810A (zh) * 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
JP6985388B2 (ja) * 2016-07-29 2021-12-22 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びそれの使用
CA3039026A1 (en) * 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3127373A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
GB201817047D0 (en) 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
JP7713953B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds
WO2021236410A1 (en) * 2020-05-19 2021-11-25 Florida State University Research Foundation, Inc. Antifibrotic compounds and related methods
IL299091A (en) 2020-08-14 2023-02-01 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and their medicinal uses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60140435A (ja) * 1983-12-28 1985-07-25 Hitachi Ltd 命令処理装置
US5099019A (en) * 1985-09-12 1992-03-24 Upjohn Company Amines useful in producing pharmaceutically active CNS compounds
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
CA2065305A1 (en) * 1989-10-25 1991-04-26 Donald E. Ayer Pharmaceutically active amino-substituted heteroaryl amines
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HUT64323A (en) * 1992-06-09 1993-12-28 Richter Gedeon Vegyeszet Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives
HU212308B (en) * 1992-06-09 1996-05-28 Richter Gedeon Vegyeszet Process for producing novel pregnane steroids and pharmaceutical compositions containing the same
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
CA2440438C (en) 2001-03-09 2011-05-03 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
DE10226943A1 (de) * 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
PT1543011E (pt) * 2002-09-06 2006-08-31 Janssen Pharmaceutica Nv Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
DE50304983D1 (de) * 2002-10-28 2006-10-19 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
US7759336B2 (en) * 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
AU2006290715A1 (en) * 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
EP1767537A1 (en) 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.

Also Published As

Publication number Publication date
TNSN08269A1 (en) 2009-10-30
ZA200805294B (en) 2009-11-25
SI1966162T1 (sl) 2017-07-31
HUE034650T2 (hu) 2018-02-28
IL191432A (en) 2014-08-31
CR10061A (es) 2008-07-17
KR20120025010A (ko) 2012-03-14
AU2006327876B2 (en) 2010-12-16
KR101152719B1 (ko) 2012-06-18
US20070185075A1 (en) 2007-08-09
NL2000323C2 (nl) 2007-11-20
EP1966162B1 (en) 2017-03-15
JP2009520019A (ja) 2009-05-21
JP5166280B2 (ja) 2013-03-21
LT1966162T (lt) 2017-07-10
ECSP088559A (es) 2008-07-30
AP2008004486A0 (en) 2008-06-30
EP1966162A2 (en) 2008-09-10
CA2634018A1 (en) 2007-06-28
DOP2006000288A (es) 2007-07-31
CA2634018C (en) 2013-10-08
WO2007072163A2 (en) 2007-06-28
AR058557A1 (es) 2008-02-13
BRPI0620201A2 (pt) 2011-11-01
AU2006327876A1 (en) 2007-06-28
CN101341134B (zh) 2013-05-01
PT1966162T (pt) 2017-06-02
NO341075B1 (no) 2017-08-21
HRP20170896T1 (hr) 2017-09-08
NO20082980L (no) 2008-08-28
PL1966162T3 (pl) 2017-09-29
TW200732306A (en) 2007-09-01
CN101341134A (zh) 2009-01-07
US7943628B2 (en) 2011-05-17
MA30082B1 (fr) 2008-12-01
NL2000323A1 (nl) 2007-06-21
CY1118987T1 (el) 2018-01-10
RS56102B1 (sr) 2017-10-31
EA200801381A1 (ru) 2009-02-27
ME00004B (me) 2010-06-10
GT200600518A (es) 2007-07-23
ES2628482T3 (es) 2017-08-03
HK1120269A1 (en) 2009-03-27
KR20080069260A (ko) 2008-07-25
PE20070848A1 (es) 2007-09-10
WO2007072163A3 (en) 2007-10-04
DK1966162T3 (en) 2017-06-19
MEP0508A (xx) 2010-02-10
RS20080278A (sr) 2009-07-15

Similar Documents

Publication Publication Date Title
UY30045A1 (es) Derivados de pirimidina
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
MX2009010071A (es) Derivados de aril isoxazolina insecticidas.
MX2010003955A (es) Derivados de pirrolidin-dionas espiroheterociclicas utiles como pesticidas.
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
GT200900003A (es) Fungicidas
NO20084583L (no) Makrosykliske kinase-inhibitorer
MX2012006994A (es) Agente antiplaquetas novedoso.
PH12012501357A1 (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
ECSP088162A (es) Mezclas pesticidas que comprenden una fenilsemicarbazona
MX2009004343A (es) Compuestos organicos.
ECSP099546A (es) Nuevos derivados tricíclicos, su procedimiento de preparación
GB0411929D0 (en) Organic compounds
MX2009004991A (es) Derivados de monoacetato de ciclopenteno-diol.
CO6280402A2 (es) Derivados de pirazol como inhibidores de 5-10
ATE496044T1 (de) Indolylmaleimidderivate
ECSP088161A (es) Mezclas pesticidas
DOP2009000214A (es) Macrolidos basados en eritromicina
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
BRPI0414972A (pt) derivados de imidazopiridinas como inibidores de no-sintase induzìvel
BRPI0414873A (pt) derivados de imidazopiridina como inibidores de no-sintase induzìveis
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
UY29879A1 (es) Derivados de 6-heteroarilpiridoindolona, su preparación y su aplicación en terapéutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160927